Industry Focus Transcripts

Last week we talked about how great U.S. Bancorp's efficiency ratio is, but PNC Bank has an even better one.

We look at recent quotes from the management teams at each company to determine whether their hopeful plans for the future should be accepted at face value by investors.

Royal Dutch Shell, ConocoPhillips, and Marathon Oil have all shed huge amounts of oil sands assets recently.

The failed attempt to repeal and replace Obamacare last month has big implications for healthcare investors.

Lessons to learn from one of the greatest bankers of our generation.

With two billion gamers worldwide and major advancements in technology, the video game industry offers plenty of opportunities for investors.

Oil prices are up, but not anywhere near where their highs of 2014 -- so why are producers increasing production by 1 million barrels?

Veeva's president discusses the cloud solution company he co-founded, from its small beginnings in healthcare CRM to its latest Vault products and expansion outside life sciences.

The team opens up their mailbag to discuss goodwill and major foodservice distributors.

Should I carry some debt on my credit card from month to month? Is trading on margin worth the risk if the rates are good? And more of your questions answered.

Dylan Lewis reports from Austin, Texas, at the SXSW conference, where he attended a session on the future of the payments industry. Tune in to hear more about the relationship between social media and existing payment processors as well as what the space might look like going forward.

After its IPO, investors would be wise to let shares of Snap cool off before dipping their toes in.

Apparently Snap's IPO has a lot of people thinking about shorting stocks -- we answer a listener question and get into the nitty gritty risks of deciding to go short.

Motley Fool veteran contributor Tyler Crowe calls in and gives a global view of the energy markets from his current location in Malawi.

The two companies share a few behind-the-scenes secrets that help make their products and services so appealing to consumers.

Digging through the company's earnings release, two Fools break down what went wrong for Fitbit last year, and what management is doing to turn things around and find growth in 2017.

Exelixis, Pacira Pharmaceuticals, Kite Pharma, Exact Sciences, and Portola Pharmaceuticals are up more than 50% in the first two months of 2017.

With Buffett’s 2016 annual letter now published, two Motley Fool analysts dig into its details.

Self-driving car technology is chugging along. Find out where we are today, and when we might actually be able to buy an autonomous car.

A lot goes into determining how much a drug will cost, but its list price is far from the only thing investors need to know.